[Cronassial in the treatment of neuropathies and atrophy of the optic nerve].
The study presents the evaluation of treatment by Cronassial of 26 patients including 16 with post-inflammatory optic atrophy, 4 with optic neuritis and 6 multiple sclerosis patients with optic neuropathy. One half of the patients showed an improvement of the visual acuity and visual field, and small improvement of the visual evoked potentials. No improvement of the conductivity of the impulses of the retino-cortical potentials has been observed. The best efficacy of the compound has been seen in the inflammatory conditions of the optic nerve.
Sobolewski
P
P
Kliniki Okulistycznej AM, Białymstoku.
D000293:Adolescent; D000328:Adult; D005074:Evoked Potentials, Visual / Q000187:drug effects*; D005260:Female; D005732:Gangliosides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009896:Optic Atrophy / Q000188:drug therapy*; D009902:Optic Neuritis / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D005732:Gangliosides; C037470:cronassial
Cronassial w leczeniu neuropatii i zaników nerwu wzrokowego.